R&D Spending Showdown: Lantheus Holdings, Inc. vs Madrigal Pharmaceuticals, Inc.

R&D Investment Trends: Lantheus vs. Madrigal

__timestampLantheus Holdings, Inc.Madrigal Pharmaceuticals, Inc.
Wednesday, January 1, 20141367300068205000
Thursday, January 1, 20151435800054218000
Friday, January 1, 20161220300015934000
Sunday, January 1, 20171812500024390000
Monday, January 1, 20181707100025389000
Tuesday, January 1, 20192001800072324000
Wednesday, January 1, 202032788000184809000
Friday, January 1, 202144966000205164000
Saturday, January 1, 2022311681000245441000
Sunday, January 1, 202377707000271823000
Loading chart...

Infusing magic into the data realm

R&D Spending Trends: A Decade of Innovation

In the competitive landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Lantheus Holdings, Inc. and Madrigal Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Madrigal Pharmaceuticals consistently outpaced Lantheus Holdings, with R&D expenses peaking at nearly 270% higher in 2023. Notably, Madrigal's R&D spending surged by over 300% from 2014 to 2023, reflecting a strategic focus on groundbreaking therapies. Meanwhile, Lantheus Holdings experienced a dramatic spike in 2022, with a 400% increase compared to its 2014 spending, before stabilizing in 2023. This data underscores the dynamic nature of R&D investment strategies and their potential impact on future growth and innovation in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025